Emerson Process Management, a global process control and automation leader and a business of Emerson, has been selected by Switzerland-based Lonza Group Ltd. to provide engineering and design services and digital automation architecture and control technologies for a new Lonza biopharmaceutical plant in Singapore. The win is part of Emerson’s growing portfolio of life sciences companies that rely on digital automation with predictive intelligence to reduce overall costs, improve reliability, ensure product quality, meet regulatory requirements, and optimize operations. “Emerson has an excellent track record in managing and controlling the highly complex processes involved in the biopharmaceutical industry,” said Steve Sonnenberg, president, Emerson Process Management. “This win is yet another example of how companies like Lonza can leverage our global resources and expertise to meet their objectives for safe, reliable, and on-time start-up of new manufacturing facilities.” In the Asia-Pacific region, Emerson also has been awarded automation contracts by Shanghai CP Guojian Pharmaceutical Co. Ltd. in China; Reliance Life Sciences, DSM Anti-Infectives India Ltd., and Biocon in India; and Lonza for a prior facility in Singapore. Having installed the automation architecture in Lonza’s first biopharmaceutical plant in Singapore, Emerson was chosen to implement its innovative PlantWeb® technologies in the new plant that is expected to be completed in 2010 at a cost of US$350 million. By following the original project models, employing best practices, and applying the experience gained during design and construction of the original facility, Emerson is expected to reduce Lonza’s overall costs for the new plant.